![Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ - Annals of Oncology Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/75420a59-c848-4f4f-aba1-dd6c26df026f/gr1.jpg)
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ - Annals of Oncology
![Breast Cancer Drug Herceptin May Work Just As Well With Much Briefer Treatment : Shots - Health News : NPR Breast Cancer Drug Herceptin May Work Just As Well With Much Briefer Treatment : Shots - Health News : NPR](https://media.npr.org/assets/img/2018/05/16/gettyimageswidecroppableherceptin_custom-5b4c96fe5d40bf3dcb8111c73150b3472d5b4784.jpg)
Breast Cancer Drug Herceptin May Work Just As Well With Much Briefer Treatment : Shots - Health News : NPR
![Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab | JACC: Heart Failure Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab | JACC: Heart Failure](https://www.jacc.org/cms/asset/a085c92a-9d23-4996-843b-475e571dabb0/gr1.jpg)
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab | JACC: Heart Failure
![Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-68205-w/MediaObjects/41598_2020_68205_Fig1_HTML.png)
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports
![Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab - ScienceDirect Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177918307054-gr3.jpg)
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab - ScienceDirect
A Designed Small Molecule Inhibitor of a Non-Coding RNA Sensitizes HER2 Negative Cancers to Herceptin | Journal of the American Chemical Society
![PPT - What's New in HER2: Current Issues in HER2 Positive Breast Cancer PowerPoint Presentation - ID:1849950 PPT - What's New in HER2: Current Issues in HER2 Positive Breast Cancer PowerPoint Presentation - ID:1849950](https://image1.slideserve.com/1849950/trastuzumab-side-effect-profile-www-herceptin-com-l.jpg)
PPT - What's New in HER2: Current Issues in HER2 Positive Breast Cancer PowerPoint Presentation - ID:1849950
![Cureus | Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy Cureus | Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy](https://assets.cureus.com/uploads/figure/file/262185/lightbox_024480701bbf11ecae3de90fdff2d364-article_river_6556cce0157f11ec9a5a1fe826b7c55d-Fig1.png)